• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov17
Merus N.V. Signs Non-exclusive Collaboration and License Agreement with Halozyme Therapeutics
13:18
Nov12
Merus N.V. to Hold Extraordinary Shareholders Meeting to Consider Genmab Acquisition Proposal
13:48
Nov10
Genmab A/S plans to issue notes and launch loans to raise funds for acquisition of Merus
12:16
Nov6
Genmab plans to acquire Merus for $800 million in a cash deal
16:02
Nov3
Goonewardene Analyzes Healthcare Company Stocks
18:21
Nov1
Merus BV released FY2025 Q3 earnings on October 31 (EST), actual revenue USD 12.15 M (forecast USD 8.678 M), actual EPS USD -1.2622 (forecast USD -1.3679)
03:00

Schedules & Filings

Schedules
Filings
Oct31
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 12.15 M, Net Income -95.52 M, EPS -1.2622

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 8.828 M, Net Income -158.22 M, EPS -2.2253

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 26.49 M, Net Income -96.47 M, EPS -1.3978

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
ASTX
46.070
+36.50%
+12.320
ABLV
0.9715
+34.87%
+0.251
View More